“gilead-sciences” Archives

in
Entry Author Date Location
Formerly Atterocor, Millendo Changes Name, Strategy—And Nabs $62M 01/05/16 Detroit Ann Arbor
Chimerix Stock Plunges After Anti-Infection Drug Fails Phase 3 Trial 12/28/15 Raleigh Durham
Pharmabros, Designer Babies, And Other Final Words For 2015 12/24/15 National
West Coast Bio Roundup: Shkreli Cuffed, KaloBios Halted & More 12/17/15 National
West Coast Bio Roundup: Gene Edit Talk, Not Poor ORIC, BioMarin Sags 12/04/15 San Francisco
West Coast Biotech Roundup: Arena, Frazier, Kura, and Theranos 10/30/15 San Diego
West Coast Biotech Roundup: Gilead, Conatus, Exelixis, and More 09/25/15 San Diego
Bristol-Myers Makes $150M Bet on Promedior, Fibrosis Drug 08/31/15 Boston
East Coast Biotech Roundup: Regeneron, Synergy, Foundation & More 07/31/15 Boston
West Coast Biotech Roundup: Juno, UCSD v. USC, Natera, LSDF & More 07/06/15 Seattle
Failed Trial for Hepatitis B Drug Leads to Layoffs at GlobeImmune 06/10/15 Boulder/Denver
Retrophin Turns Asklepion Voucher Into $245M Sanofi Payday 05/27/15 New York
West Coast Biotech Roundup: Orexigen, Denali, Nant, ASCO & More 05/15/15 San Diego
West Coast Biotech Roundup: Adaptive, Gilead, Juno, aTyr & More 05/08/15 Boston
The Innovation Challenge: Assessing BioPharma Startups 05/04/15 Seattle
Pop That Bubble: 5 Reasons Biotech Needs A Different Metaphor 04/14/15 National
Garabedian’s Rocky Road at Sarepta Ends With Abrupt Resignation 04/01/15 Boston
With Asklepion Deal, Retrophin Gets a New Drug—And a Voucher 03/18/15 New York
With $43M, Nimbus Sheds “Discovery” Tag, Heads to First Clinical Test 03/18/15 Boston
East Coast Biotech Roundup: Sync Project, Epizyme, Bristol & More 03/16/15 Boston
CTI Goes Up, And Down, And Back Up On Phase 3 Myelofibrosis News 03/09/15 Seattle
AbbVie Snaps up Pharmacyclics, Pays Whopping $21B For Cancer Drug 03/05/15 National
Tiger Teams, Dropping Subs, and Biotech’s Elusive Second Strikes 03/03/15 National
Chimerix Drug Shows Promise As Virus Fighter for Transplant Patients 03/02/15 Raleigh Durham
Vertex Buys Spine Drug on the QT As Part of Its Post-Hep C Makeover 02/20/15 Boston
West Coast Biotech Roundup: Dendreon, Invitae, Juno, Regulus & More 02/12/15 Seattle
Gilead Exec: More Value in Quick Hep C Cure than Cancer Treatments 02/10/15 San Francisco
East Coast Biotech Roundup: Hamburg, Merck, Annovation, WaVe & More 02/09/15 Boston
J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex 01/16/15 National
West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More 01/08/15 San Francisco
Page 3 of 10 « previous page · next page »